Trial Profile
A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2018
Price :
$35
*
At a glance
- Drugs Micafungin (Primary)
- Indications Candidaemia; Invasive candidiasis
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 27 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 19 Nov 2013 New trial record